Metagenomi, Inc. (MGX) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1/A registration statement. Metagenomi, Inc. is backed by major pharma firms as strategic investors and partners and is well-capitalized but is operating in a high-risk research area characterized by a slow-moving U.S. FDA for genetic treatments. Emeryville, California-based Metagenomi Technologies was founded to create a "comprehensive genome editing toolbox" to help treat diseases through genetic alterations.